Industry Briefs: May 7, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: May 7, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Almac has installed an Uhlmann high-speed blister line in its new US commercial packaging facility. Read More

Celsion has signed a long-term commercial-supply agreement with Zhejiang Hisun Pharmaceutical for the production of ThermoDox, a heat-activated liposomal encapsulation of doxorubicin. Read More

Evotec has signed a compound-management agreement with the US Environmental Protection Agency. The contract covers a period of five years and has a total value of up to EUR 7.7 million ($10 million). Read More

Grain Processing Corporation (GPC) has opened its new Solutions Center, located in the Technical Development Center at GPC headquarters in Muscatine, Iowa. Read More

Lorus Therapeutics and Genentech have signed a global intellectual property license agreement for IL-17E, a drug for treating cancer. Read More

Marina Biotech has announced a worldwide exclusive licensing agreement with Monsanto for Marina Biotech’s delivery and chemistry technologies. Read More

Pii has provided funding for hot-melt extrusion capabilities at the University of Mississippi. Read More

Sartorius Stedim Biotech and c-LEcta have signed a sales and distribution agreement for c-LEcta’s proprietary Serratia marcescens nuclease for biopharmaceutical applications. Read More

SGS Life Science Services has announced the availability of preformulation and formulation services at its laboratory in Lincolnshire, Illinois.

People News

Althea Technologies has appointed Kristin DeFife as director of biologics manufacturing and Jack Wright as vice-president of sales and marketing. Read More

Covance has announced several executive appointments. Read More

EMD Millipore has appointed Andrew Bulpin as head of the company’s process solutions business unit. Read More

GlaxoSmithKline named James Shannon chief medical officer, effective May 1, 2012. Read More

In other news, GlaxoSmithKline has appointed Lynn Elsenhans and Jing Ulrich to its board as nonexecutive directors, effective July 1, 2012. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here